New drug for Alzheimer’s disease shows promise in phase 3 trial
Sep 28, 2022
Lecanemab is a monoclonal antibody drug designed to target and help remove Alzheimer’s-associated amyloid plaques in the brain.
Biogen cuts price of controversial Aduhelm in half
Dec 21, 2021
The drug shows promise in clearing the brain plaques believed to play a role in Alzheimer’s disease.
Changes in Alzheimer’s biomarkers tied to withdrawal of PAP for OSA
Jul 08, 2022
An increase in neurofilament light and a decrease in Aβ40 were associated with withdrawal of positive airway pressure for obstructive sleep apnea.
PET changes similar for Alzheimer’s disease, Down syndrome
Dec 20, 2022
“This study shows that, although there are subtle differences, Alzheimer’s disease pathophysiology is similar among people with Down syndrome and people with autosomal dominant Alzheimer’s...
Second death in trial of experimental Alzheimer’s drug raising concerns
Nov 29, 2022
Doctors suspect that by stripping away amyloid deposits, lecanemab weakens blood vessels and leaves them vulnerable to bleeds.
Appendicular lean mass linked to decrease in Alzheimer’s risk
Jul 10, 2023
A higher appendicular lean mass also was associated with increased cognitive performance.
Intranasal insulin may have pro-cognitive benefits
Jun 30, 2023
Improvement in global cognition was seen for patients with Alzheimer’s disease/mild cognitive impairment, but no effects were seen for healthy individuals or other patient populations.
Medicare mulls coverage for controversial drug for Alzheimer’s disease
Jul 13, 2021
CMS says a final decision on coverage is not likely until next spring.
Light therapy aids psychobehavioral symptoms with Alzheimer’s disease
Dec 08, 2023
Significant benefits were seen for sleep efficacy, depression and agitation.
Routine vaccines can cut risk for later Alzheimer’s disease
Aug 23, 2023
The findings were seen for tetanus and diphtheria, shingles and pneumococcus vaccines.